Inventor · disambiguated record
John Scholler
Also filed as: SCHOLLER JOHN
22 granted patents·9 pending applications·502 citations·filing 2000–2025
96Inventor score
Top patents by PatentIndex Score
31 records- 0197US9573988B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsBROGDON JENNIFER·Filed 2014·Granted Feb 21, 2017·87 cites·94 claims
- 0296US10040846B2Compositions and methods for generating a persisting population of T cells useful for the treatment of cancerUNIV PENNSYLVANIA·Filed 2013·Granted Aug 7, 2018·39 cites·3 claims
- 0396US9394368B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorBROGDON JENNIFER·Filed 2014·Granted Jul 19, 2016·112 cites·38 claims
- 0495US10927184B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 23, 2021·10 cites·26 claims
- 0595US10221245B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted Mar 5, 2019·36 cites·67 claims
- 0695US9783591B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2013·Granted Oct 10, 2017·33 cites·2 claims
- 0795US9714278B2Use of ICOS-based CARs to enhance antitumor activity and CAR persistenceUNIV PENNSYLVANIA·Filed 2013·Granted Jul 25, 2017·34 cites·18 claims
- 0895US9365641B2Compositions and methods for targeting stromal cells for the treatment of cancerUNIV PENNSYLVANIA·Filed 2013·Granted Jun 14, 2016·54 cites·26 claims
- 0993US11597754B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2019·Granted Mar 7, 2023·4 cites·20 claims
- 1093US6565856B1Compounds and methods for treatment and diagnosis of chlamydial infectionCORIXA CORP·Filed 2000·Granted May 20, 2003·64 cites·4 claims
- 1192US11299536B2Compositions and methods for generating a persisting population of T cells useful for the treatment of cancerUNIV PENNSYLVANIA·Filed 2018·Granted Apr 12, 2022·5 cites·22 claims
- 1291US12234274B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2021·Granted Feb 25, 2025·1 cites·23 claims
- 1391US11028177B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsNOVARTIS AG·Filed 2017·Granted Jun 8, 2021·4 cites·47 claims
- 1490US10800840B2Compositions and methods for generating a persisting population of T cells useful for the treatment of cancerUNIV PENNSYLVANIA·Filed 2018·Granted Oct 13, 2020·4 cites·14 claims
- 1590US10501519B2Use of the CD2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2017·Granted Dec 10, 2019·6 cites·3 claims
- 1689US10308717B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Jun 4, 2019·4 cites·9 claims
- 1788US11865167B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2019·Granted Jan 9, 2024·2 cites·39 claims
- 1884US2025295774A1Compositions and methods for generating a persisting population of t cells useful for the treatment of cancerUNIV PENNSYLVANIA·Filed 2025·Application pending·0 cites
- 1983US10577407B2Use of ICOS-based CARS to enhance antitumor activity and CAR persistenceUNIV PENNSYLVANIA·Filed 2017·Granted Mar 3, 2020·3 cites·15 claims
- 2083US2024301024A1Use of icos-based cars to enhance antitumor activity and car persistenceUNIV PENNSYLVANIA·Filed 2024·Application pending·0 cites
- 2181US2023242612A1Use of the cd2 signaling domain in second-generation chimeric antigen receptorsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2279US2023416408A1Compositions and Methods for Targeting Stromal Cells for the Treatment of CancerUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2377US2025215096A1Chimeric antigen receptor therapy in combination with il-15r and il15NOVARTIS AG·Filed 2024·Application pending·0 cites
- 2476US12350334B2Compositions and methods for generating a persisting population of T cells useful for the treatment of cancerUNIV PENNSYLVANIA·Filed 2021·Granted Jul 8, 2025·0 cites·15 claims
- 2573US11718685B2Compositions and methods for targeting stromal cells for the treatment of cancerUNIV PENNSYLVANIA·Filed 2019·Granted Aug 8, 2023·0 cites·8 claims
- 2670US11958892B2Use of ICOS-based cars to enhance antitumor activity and car persistenceUNIV PENNSYLVANIA·Filed 2020·Granted Apr 16, 2024·0 cites·7 claims
- 2762US2020399383A1Chimeric antigen receptor therapy in combination with il-15r and il15NOVARTIS AG·Filed 2019·Application pending·0 cites
- 2858US10329355B2Compositions and methods for targeting stromal cells for the treatment of cancerUNIV PENNSYLVANIA·Filed 2016·Granted Jun 25, 2019·0 cites·9 claims
- 2957US2024122981A1CCR4-Targeting Chimeric Antigen Receptor Cell TherapyUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3049US2021038659A1Combination therapy using a chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3136US2017209492A1Subset-optimized chimeric antigen receptor-containing t-cellsJUNE CARL H·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Scholler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →